A Study of a Digital Therapeutic as Antipsychotic Therapy for Schizophrenia (H-53368)
A Multicenter, Randomized, Double-Blind, Parallel-Group, Controlled, 16-week Study to Evaluate the Efficacy and Safety of a Digital Therapeutic (CT-155) as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants with Experiential Negative Symptoms of Schizophrenia
Have you been struggling to feel motivated?
Have you heard about the Convoke Study? People diagnosed with schizophrenia talk about their struggles with motivation and finding enjoyment in things. These are common negative symptoms of schizophrenia.
Standard treatment for schizophrenia involves a combination of medication and therapy.
The Convoke Study will look at two mobile applications (apps) to see if they can support people with moderate to severe negative schizophrenia symptoms.
We are looking for people who:
- Are at least 18 years of age
- Have a primary diagnosis of schizophrenia
- Have been on a stable dose of antipsychotic medication for at least 12 weeks before the study treatment period
- Own a smartphone compatible with Android 10 or greater, or iOS 14 or greater
To participate in the study, you must be available to use a mobile app for up to 22 weeks. The study also includes four study center assessment visits and three phone calls.
You will receive all study-related care and the study app at no cost. Reimbursement for study-related travel expenses or a stipend for your time and cell phone charges may be available. A team of healthcare professionals will monitor your condition during the study.